
July to September 2025
| Drug Name | Government Contribution Dollars | Prescriptions |
|---|---|---|
| PEMBROLIZUMAB | $176,086,545 | 20,753 |
| ELEXACAFTOR + TEZACAFTOR + IVACAFTOR (&) IVACAFTOR | $162,440,329 | 7,997 |
| DUPILUMAB | $143,651,206 | 83,767 |
| AFLIBERCEPT | $121,031,939 | 123,464 |
| NIVOLUMAB | $106,217,534 | 14,917 |
| SEMAGLUTIDE | $93,405,394 | 773,842 |
| UPADACITINIB | $83,809,660 | 56,840 |
| USTEKINUMAB | $79,078,378 | 21,151 |
| APIXABAN | $74,872,362 | 1,148,664 |
| DENOSUMAB | $65,853,192 | 312,638 |
| OCRELIZUMAB | $62,372,072 | 3,812 |
| DARATUMUMAB | $60,116,586 | 8,409 |
| Drug Name | Government Contribution Dollars | Prescriptions |
|---|---|---|
| ROSUVASTATIN | $35,091,512 | 4,171,758 |
| PANTOPRAZOLE | $26,064,061 | 2,803,135 |
| ATORVASTATIN | $26,483,414 | 2,786,223 |
| ESOMEPRAZOLE | $20,320,902 | 1,970,396 |
| ESCITALOPRAM | $8,386,952 | 1,644,633 |
| SERTRALINE | $8,623,595 | 1,586,854 |
| PERINDOPRIL | $12,952,738 | 1,580,474 |
| METFORMIN | $14,190,450 | 1,552,068 |
| AMOXICILLIN | $6,788,139 | 1,550,283 |
| CEFALEXIN | $7,998,081 | 1,299,101 |
| AMLODIPINE | $10,513,943 | 1,216,003 |
| APIXABAN | $74,872,362 | 1,148,664 |
| Contributor | Contribution Dollars |
|---|---|
| Australian Government | $5,147,571,465 |
| Patients | $920,561,311 |